Will FTC Injunction Against Shkreli’s Company Deter Brands From Pursuing Anti-Generic Actions?
Executive Summary
Other companies have largely halted practices at issue in the ‘diabolical anticompetitive plan’ undertaken by Shkreli’s former firm. FTC did not challenge the price hike for Daraprim itself, but did cite an effort to block release of sales data and other tactics to discourage generics.